A Randomized Double-Blinded Placebo-Controlled Exploratory Study of Intravenous Immunoglobulin (NewGam 10%) in Amnestic Mild Cognitive Impairment

Trial Profile

A Randomized Double-Blinded Placebo-Controlled Exploratory Study of Intravenous Immunoglobulin (NewGam 10%) in Amnestic Mild Cognitive Impairment

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Amnesia; Mild cognitive impairment
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2018 Planned End Date changed from 1 Nov 2017 to 1 Jul 2018.
    • 14 Dec 2012 Planned End Date changed from 1 Jan 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
    • 14 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top